Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

Home Case Index All Cases Central Excise Central Excise + SC Central Excise - 2012 (3) TMI SC This

  • Login
  • Plus+
  • Cases Cited
  • Referred In
  • Summary

Forgot password       New User/ Regiser

⇒ Register to get Live Demo



 

2012 (3) TMI 40 - SC - Central Excise


  1. 2023 (5) TMI 290 - SC
  2. 2023 (5) TMI 191 - SC
  3. 2020 (5) TMI 63 - SC
  4. 2016 (7) TMI 1057 - SC
  5. 2015 (8) TMI 1012 - SC
  6. 2014 (3) TMI 821 - SC
  7. 2023 (12) TMI 757 - HC
  8. 2023 (5) TMI 855 - HC
  9. 2021 (5) TMI 327 - HC
  10. 2020 (6) TMI 549 - HC
  11. 2020 (2) TMI 1247 - HC
  12. 2019 (5) TMI 204 - HC
  13. 2018 (7) TMI 668 - HC
  14. 2018 (3) TMI 1326 - HC
  15. 2017 (7) TMI 148 - HC
  16. 2015 (4) TMI 118 - HC
  17. 2014 (12) TMI 1408 - HC
  18. 2015 (2) TMI 751 - HC
  19. 2014 (10) TMI 449 - HC
  20. 2013 (9) TMI 938 - HC
  21. 2012 (12) TMI 908 - HC
  22. 2024 (8) TMI 331 - AT
  23. 2024 (7) TMI 685 - AT
  24. 2024 (1) TMI 1171 - AT
  25. 2024 (1) TMI 147 - AT
  26. 2023 (3) TMI 902 - AT
  27. 2022 (12) TMI 1049 - AT
  28. 2022 (9) TMI 674 - AT
  29. 2021 (10) TMI 231 - AT
  30. 2021 (2) TMI 565 - AT
  31. 2020 (3) TMI 492 - AT
  32. 2020 (2) TMI 1196 - AT
  33. 2019 (12) TMI 522 - AT
  34. 2019 (7) TMI 12 - AT
  35. 2019 (5) TMI 216 - AT
  36. 2019 (2) TMI 505 - AT
  37. 2018 (7) TMI 1048 - AT
  38. 2017 (9) TMI 943 - AT
  39. 2018 (2) TMI 611 - AT
  40. 2016 (1) TMI 1153 - AT
  41. 2015 (1) TMI 208 - AT
  42. 2014 (12) TMI 33 - AT
  43. 2024 (3) TMI 625 - AAAR
  44. 2024 (5) TMI 1247 - AAAR
  45. 2024 (5) TMI 1209 - AAAR
  46. 2022 (3) TMI 1045 - AAAR
  47. 2022 (3) TMI 974 - AAAR
  48. 2022 (3) TMI 679 - AAAR
  49. 2022 (3) TMI 624 - AAAR
  50. 2022 (3) TMI 576 - AAAR
  51. 2021 (7) TMI 265 - AAAR
  52. 2021 (7) TMI 264 - AAAR
  53. 2020 (5) TMI 284 - AAAR
  54. 2020 (1) TMI 882 - AAAR
  55. 2018 (8) TMI 393 - AAAR
  56. 2023 (11) TMI 765 - AAR
  57. 2023 (9) TMI 727 - AAR
  58. 2023 (9) TMI 125 - AAR
  59. 2023 (7) TMI 702 - AAR
  60. 2023 (11) TMI 68 - AAR
  61. 2022 (8) TMI 807 - AAR
  62. 2022 (9) TMI 782 - AAR
  63. 2022 (3) TMI 179 - AAR
  64. 2021 (12) TMI 887 - AAR
  65. 2021 (7) TMI 536 - AAR
  66. 2021 (3) TMI 141 - AAR
  67. 2021 (3) TMI 140 - AAR
  68. 2021 (1) TMI 590 - AAR
  69. 2020 (6) TMI 183 - AAR
  70. 2019 (7) TMI 38 - AAR
  71. 2018 (10) TMI 1871 - AAR
  72. 2018 (10) TMI 1312 - AAR
  73. 2018 (12) TMI 141 - AAR
Issues Involved:
1. Classification of products under the Central Excise Tariff Act, 1985.
2. Determination of whether Povidone Iodine Cleansing Solution USP and Wokadine Surgical Scrub are medicaments or detergents.
3. Interpretation of relevant tariff headings and sub-headings.
4. Application of common parlance and commercial usage tests.
5. Examination of the primary and essential use of the products.
6. Consideration of the composition and labeling of the products.
7. Review of previous judgments and legal principles for classification.

Detailed Analysis:

1. Classification of Products under the Central Excise Tariff Act, 1985:
The primary issue in these appeals is the classification of two products, Povidone Iodine Cleansing Solution USP and Wokadine Surgical Scrub, for the purpose of levy of duty under the Central Excise Tariff Act, 1985. The assessee claims these products are medicaments and should be classified under Chapter sub-heading 3003, while the revenue contends they are detergents and should be classified under Chapter sub-heading 3402.90.

2. Determination of Whether Products are Medicaments or Detergents:
The assessee manufactures Povidone Iodine Cleansing Solution USP and Wokadine Surgical Scrub, which have identical compositions but differ in branding. The Adjudicating Authority issued show cause notices alleging misclassification under Chapter sub-heading 3003.10/20 instead of 3402.90, suggesting the products are primarily used as detergents rather than medicaments.

3. Interpretation of Relevant Tariff Headings and Sub-headings:
The relevant tariff items under Chapter sub-heading 3003 and 3402.90 are examined. Chapter Note 2(i) of Chapter 30 defines "medicament" as products mixed or compounded for therapeutic or prophylactic uses. The products in question contain Povidone Iodine along with Neutronix, Superamide, and Sodium Hydroxide.

4. Application of Common Parlance and Commercial Usage Tests:
The Tribunal considered the wide range of literature on the products, their composition, and user, concluding that Povidone Iodine Cleansing Solution USP is used as an antiseptic and disinfectant. The Tribunal rejected the revenue's contention that the addition of surface active agents rendered the products as washing solutions, emphasizing their primary use in medical settings.

5. Examination of the Primary and Essential Use of the Products:
The Tribunal observed that the products are not used as general cleansing solutions but in places where surgery and medicine are practiced. The labeling indicates preoperative use by surgeons and patients, supporting the classification as medicaments.

6. Consideration of the Composition and Labeling of the Products:
The products' labels and compositions were scrutinized, showing they contain Povidone Iodine, Neutronix, Superamide, and Sodium Hydroxide. Various pharmacopeias and medical dictionaries were referenced to highlight the therapeutic and prophylactic properties of Povidone Iodine.

7. Review of Previous Judgments and Legal Principles for Classification:
The judgment references several Supreme Court decisions, emphasizing that the classification of products should consider their primary and essential use, common parlance, and commercial usage. The Tribunal's decision to classify the products under Chapter sub-heading 3003 was upheld, as they are primarily intended and used for their antiseptic properties.

Conclusion:
The Supreme Court confirmed the Tribunal's order, rejecting the revenue's appeals and classifying Povidone Iodine Cleansing Solution USP and Wokadine Surgical Scrub as medicaments under Chapter sub-heading 3003. The decision was based on the products' composition, labeling, primary use in medical settings, and the application of common parlance and commercial usage tests.

 

 

 

 

Quick Updates:Latest Updates